Related Experiment Video
Updated: May 29, 2026
08:09
Psychophysiological Assessment of the Effectiveness of Emotion Regulation Strategies in Childhood
Published on: February 11, 2017
Efficacy assessment in paediatric studies.
Siri Wang1, Pirjo Laitinen-Parkkonen
1Norwegian Medicines Agency, Tønsberg Hospital Pharmacy, Sven Oftedalsvei 6, N-0950 Oslo, Norway. siri.wang@noma.no
Handbook of Experimental Pharmacology
|September 2, 2011
Summary
Extrapolating adult efficacy data to children is challenging due to developmental differences. New pediatric trial endpoints and validated surrogate endpoints are crucial for accurate treatment assessment.
Area of Science:
- Pediatric clinical pharmacology
- Drug development and regulation
- Biomarker and endpoint validation
Background:
- Regulatory authorities permit some extrapolation of adult efficacy data to pediatric populations.
- However, disease processes and developmental stages in children often preclude direct efficacy extrapolation.
- This necessitates tailored approaches for evaluating treatment effectiveness in pediatric patients.
Purpose of the Study:
- To highlight the challenges in extrapolating adult clinical trial data to pediatric populations.
- To emphasize the need for developing and validating specific endpoints for pediatric studies.
- To advocate for the creation of surrogate endpoints for benefit-risk assessment in children.
Main Methods:
- Discussion of the limitations of using adult clinical endpoints in pediatric trials.
- Consideration of developmental stages and their impact on endpoint performance and interpretation.
- Exploration of the necessity for age- and subgroup-specific outcome measures.
Main Results:
- Standard clinical endpoints used in adult trials may not be suitable or sensitive for pediatric populations.
- Children's continuous development significantly influences how endpoints reflect treatment efficacy.
- The development of validated surrogate endpoints is essential for pediatric drug evaluation.
Conclusions:
- Pediatric drug development requires specialized endpoints that account for child development.
- Validated biomarkers and surrogate endpoints are critical for accurate pediatric benefit-risk assessment.
- Collaboration among researchers, industry, and regulatory bodies is vital for addressing these challenges.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.